Your browser doesn't support javascript.
loading
The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer.
Banavar, Guruduth; Ogundijo, Oyetunji; Toma, Ryan; Rajagopal, Sathyapriya; Lim, Yen Kai; Tang, Kai; Camacho, Francine; Torres, Pedro J; Gline, Stephanie; Parks, Matthew; Kenny, Liz; Perlina, Ally; Tily, Hal; Dimitrova, Nevenka; Amar, Salomon; Vuyisich, Momchilo; Punyadeera, Chamindie.
Afiliación
  • Banavar G; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA. guru@viome.com.
  • Ogundijo O; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Toma R; Viome Research Institute, Viome Life Sciences, Inc., Seattle, USA.
  • Rajagopal S; Viome Research Institute, Viome Life Sciences, Inc., Seattle, USA.
  • Lim YK; The Saliva and Liquid Biopsy Translational Laboratory, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Tang K; The Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia.
  • Camacho F; The Saliva and Liquid Biopsy Translational Laboratory, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
  • Torres PJ; The Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia.
  • Gline S; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Parks M; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Kenny L; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Perlina A; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Tily H; The School of Medicine, University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Dimitrova N; Viome Research Institute, Viome Life Sciences, Inc., Seattle, USA.
  • Amar S; Viome Research Institute, Viome Life Sciences, Inc., New York City, USA.
  • Vuyisich M; New York Medical College, Valhalla, NY, USA.
  • Punyadeera C; New York Medical College, Valhalla, NY, USA.
NPJ Genom Med ; 6(1): 105, 2021 Dec 08.
Article en En | MEDLINE | ID: mdl-34880265
ABSTRACT
Despite advances in cancer treatment, the 5-year mortality rate for oral cancers (OC) is 40%, mainly due to the lack of early diagnostics. To advance early diagnostics for high-risk and average-risk populations, we developed and evaluated machine-learning (ML) classifiers using metatranscriptomic data from saliva samples (n = 433) collected from oral premalignant disorders (OPMD), OC patients (n = 71) and normal controls (n = 171). Our diagnostic classifiers yielded a receiver operating characteristics (ROC) area under the curve (AUC) up to 0.9, sensitivity up to 83% (92.3% for stage 1 cancer) and specificity up to 97.9%. Our metatranscriptomic signature incorporates both taxonomic and functional microbiome features, and reveals a number of taxa and functional pathways associated with OC. We demonstrate the potential clinical utility of an AI/ML model for diagnosing OC early, opening a new era of non-invasive diagnostics, enabling early intervention and improved patient outcomes.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: NPJ Genom Med Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: NPJ Genom Med Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos